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Background: One of the most important objectives of the clinical cancer research is to diagnose cancer more
accurately based on the patients’ gene expression profiles. Both Cox proportional hazards model (Cox) and
accelerated failure time model (AFT) have been widely adopted to the high risk and low risk classification or
survival time prediction for the patients’ clinical treatment. Nevertheless, two main dilemmas limit the accuracy
of these prediction methods. One is that the small sample size and censored data remain a bottleneck for training
robust and accurate Cox classification model. In addition to that, similar phenotype tumours and prognoses are
actually completely different diseases at the genotype and molecular level. Thus, the utility of the AFT model
for the survival time prediction is limited when such biological differences of the diseases have not been
previously identified.
Methods: To try to overcome these two main dilemmas, we proposed a novel semi-supervised learning method
based on the Cox and AFT models to accurately predict the treatment risk and the survival time of the patients.
Moreover, we adopted the efficient L1/2 regularization approach in the semi-supervised learning method to select
the relevant genes, which are significantly associated with the disease.
Results: The results of the simulation experiments show that the semi-supervised learning model can significant improve
the predictive performance of Cox and AFT models in survival analysis. The proposed procedures have been successfully
applied to four real microarray gene expression and artificial evaluation datasets.
Conclusions: The advantages of our proposed semi-supervised learning method include: 1) significantly increase the
available training samples from censored data; 2) high capability for identifying the survival risk classes of patient in Cox
model; 3) high predictive accuracy for patients’ survival time in AFT model; 4) strong capability of the relevant
biomarker selection. Consequently, our proposed semi-supervised learning model is one more appropriate tool for
survival analysis in clinical cancer research.
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An important objective of clinical cancer research is to
develop tools to accurately predict the survival time and
risk profile of patients based on the DNA microarray
data and various clinical parameters. There are several
existing techniques in the literature for performing this
type of survival analysis. Among of them, both Cox pro-
portional hazards model (Cox) [1] and the accelerated
failure time model (AFT) [2] have been widely used. Cox
model is the most popular approach by far in survival
analysis to assess the significance of various genes in the
survival risk of patients through the hazard function. On
the other hand, the requirement for analyzing failure
time data arises in investigating the relationship between
a censored survival outcome and high-dimensional
microarray gene expression profiles. Therefore, AFT
model has been studied extensively in recent years.
However, various current cancer survival analysis mech-
anisms have not demonstrated themselves to be very ac-
curate as expected. The accuracy problems, in essence,
are related to some fundamental dilemmas in cancer
survival analysis. We believe any attempt to improve the
accuracy of survival analysis method has to compromise
between these two dilemmas:
 The small sample size and censored survival data
versus high dimensional covariates dilemma in Cox
model
High-dimensional survival analysis in particular has
attracted much interest due to the popularity of micro-
array studies involving survival data. This is statistically
challenging because the number of genes, p, is typically
hundreds of times larger than the number of microarray
samples, n (p> > n). For survival analysis, sample size is
reduced significantly by the availability of follow-up data
for the analyzed samples. In fact, in publicly available
gene expression databases, only a small fraction of
human-tumor microarray datasets provides clinical
follow-up data. A “low-risk” or “high-risk” classification
based on Cox model usually relies on traditional super-
vised learning techniques, in which only completed data
(i.e., data from samples with clinical follow-up) can be
used for learning, while censored data (i.e., data from
samples without clinical follow-up) are disregarded.
Thus, the small sample size and censored survival data
remain a bottleneck in obtaining robust and accurate
classifiers with Cox model. Recently a technique called
semi-supervised learning [3] in machine learning sug-
gests that censored data, when used in conjunction with
limited amount of completed data, can produce consid-
erable improvement in learning accuracy. Indeed, semi-
supervised learning has been proved to be effective in
solving different biological problems, such as proteinclassification [4, 5], drug-protein interaction prediction
[6] and prediction of interactions between disease and
human proteins [7]. Moreover, there are some semi-
supervised learning approaches worked on the gene
expression data. For example, “corrected” Cox scores
were used for semi-supervised prediction using princi-
pal component regression by Bair and Tibshirani [8]
and the semi-supervised classification using nearest-
neighbor shrunken centroid clustering by Tibshirani
et al. [9].
 The similar phenotype disease versus different
genotype cancer dilemma in the AFT model
In the accelerated failure time model, to increase the
available sample size and get the more accurate result,
each censored observation time is replaced with the
imputed value using some estimators, such as the in-
verse probability weighting (IPW) [10] method, mean
imputation method, Buckley-James method [11] and
rank-based method. In fact, these estimation methods
assume that the AFT model was used for the patients
with similar phenotype cancer, and the survival times
should satisfy the same unspecified common probability
distribution. Nevertheless, the disparity we see in disease
progression and treatment response can be attributed to
that the similar phenotype cancer may be completely
different diseases on the molecular genotype level. So we
need to identify different cancer genotypes. Can we do it
based exclusively on the clinical data? For example, pa-
tients can be assigned to a “low-risk” or a “high-risk”
subgroup based on whether they were still alive or
whether their tumour had metastasized after a certain
amount of time. This approach has also been used to
develop procedures to diagnose patients [12]. However,
by dividing the patients into subgroups just based on
their survival times, the resulting subgroups may not be
biologically meaningful. Suppose, for example, the
underlying cell types of each patient are unknown. If we
were to assign patients to “low-risk” and “high-risk” sub-
groups based on their survival times, many patients
would be assigned to the wrong subgroup, and any fu-
ture predictions based on this model would be suspect.
Therefore, we need propose more accurate classification
methods by identifying these underlying cancer subtypes
based on microarray data and clinical data together, and
build a model that can determine which subtype is
present in future patients.
Our idea in this study is to strike a tactical balance
between the two contradictory dilemmas. We propose a
novel semi-supervised learning method based on the
combination of Cox and AFT models with L1/2
regularization for high-dimensional and low sample size
biological data. In our semi-supervised learning framework,
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subgroup though samples as many as possible to
improve its predictive accuracy. Meanwhile, the AFT
model can estimate the censored data in the subgroup,
in which the samples have the same molecular
genotype.Methods
Cox proportional hazards model (Cox)
The Cox proportional hazards model is now the most
widely used for survival analysis to classify the pa-
tients into “low-risk” or “high-risk” subgroup after
prognostic. Under the Cox model, the hazard function
for the covariate matrix x with sample size n and the
number of genes p is specified as λ(t) = λ0(t)exp(β′x),
where t is the survival time and the baseline hazard
function λ0(t) is common to all subjects, but is un-
specified or unknown. Let ordered risk set at time
t(r) be denoted by Rr = {j∈1,…, n:tj ≥ t(r)}. Assume that
censoring is non informative and that there are no
tied event times. The Cox log partial likelihood can














Where D denotes the set of indices for observed events.
Accelerated failure time model (AFT)
The AFT model is a linear regression model for survival
analysis, in which the logarithm of response ti is related
linearly to covariates xi:
h tið Þ ¼ β0 þ xi′βþ εi; i ¼ 1;…; n; ð2Þ
where h(.) is the log transformation or some other
monotone function. In this case, the Cox assumption of
multiplicative effect on hazard function is replaced with
the assumption of multiplicative effect on outcome. In
other words, it is assumed that the variables xi act multi-
plicatively on time and therefore affect the rate at which
individual i proceeds along the time axis. Because cen-
soring is present, the standard least squares approach
cannot be employed to estimate the regression parame-








































Fig. 2 The percentage of different types of samples in original datasets and the datasets processed by our semi-supervised learning approach
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the replacement of censored ti with imputed values. In
order to simplify the method, we use Kaplan-Meier weight
approach to estimate the censored data in the least square
criterion. Since for high dimensional and low simple size
data, the Kaplan-Meier weight estimator is more efficient
than the Buckley-James and rank based approaches.
Moreover, it also has rigorously and strong theoretical jus-
tifications under reasonable conditions [13]. For each cen-
sored ti with the conditional expectation of tj given tj > ti
[14], the imputed value h(ti) can then be given by
h ti
  ¼ δið Þh tið Þ
þ 1−δið Þ S^ tið Þ
 −1X
t rð Þ>ti
h t rð Þ
 










Fig. 3 The IBS obtained by the Cox and AFT models with and without semwhere Ŝ is the Kaplan-Meier estimator (Kaplan and
Meier, 1958) of the survival function and ΔŜ(t(r)) is the
step of Ŝ at time t(r) [15].
L1/2 regularization
In recent years, various regularization methods for sur-
vival analysis under the Cox and AFT models have been
proposed, which perform both continuous shrinkage and
automatic gene selection simultaneously. For example,
Cox-based methods utilizing kernel transformations
[16], threshold gradient descent minimization [17], and
lasso penalization [18] have been proposed. Likewise, a
few authors have proposed variable selection methods
based on accelerated failure time models. Most of these pro-
cedures are based on L1 -norm, however, the results of L1





i-supervised learning approach for the four gene expression datasets
Table 1 The performance of the Cox and AFT models with and without the semi-supervised learning approach in simulated
experiment (the average numbers and the standard deviations (in brackets) were listed in 50 runs)
Cor. Size Cox Semi-Cox
Correct Selected Precision Correct Selected Precision
100 4.06 (1.39) 24.44 (4.65) 0.166 (0.044) 6.58 (1.41) 16.96 (6.41) 0.388 (0.080)
ρ = 0 200 5.62 (1.64) 28.22 (6.16) 0.199 (0.031) 8.68 (1.56) 17.84 (5.72) 0.487 (0.078)
300 8.02 (1.43) 35.18 (5.81) 0.228 (0.029) 9.76 (0.98) 19.02 (5.41) 0.513 (0.087)
100 3.90 (1.43) 24.38 (5.83) 0.159 (0.041) 6.46 (1.37) 17.08 (6.05) 0.378 (0.075)
ρ = 0.3 200 5.68 (1.42) 29.64 (6.19) 0.192 (0.035) 8.62 (1.11) 17.86 (5.45) 0.483 (0.074)
300 7.84 (1.55) 35.86 (5.96) 0.219 (0.037) 9.42 (0.68) 18.54 (5.10) 0.508 (0.082)
Cor. Size AFT Semi-AFT
Correct Selected Precision Correct Selected Precision
100 5.02 (1.61) 38.74 (6.27) 0.130 (0.029) 6.84 (1.37) 35.52 (6.17) 0.192 (0.031)
ρ = 0 200 7.12 (1.30) 46.68 (6.03) 0.152 (0.025) 8.84 (1.18) 42.16 (5.38) 0.210 (0.039)
300 8.90 (0.99) 56.54 (6.85) 0.157 (0.019) 9.86 (0.46) 50.84 (5.49) 0.194 (0.027)
100 4.74 (1.19) 39.54 (5.88) 0.120 (0.030) 6.72 (1.43) 35.84 (6.43) 0.188 (0.033)
ρ = 0.3 200 6.98 (1.50) 47.02 (6.32) 0.148 (0.024) 8.78 (1.02) 44.96 (6.95) 0.195 (0.031)
300 8.80 (1.02) 56.82 (6.30) 0.155 (0.022) 9.78 (0.50) 49.31 (5.86) 0.198 (0.034)
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regularization with the lower value of q would lead to bet-
ter solutions with more sparsity. Moreover, among Lq
regularizations with q ∈ (0, 1), only L1/2 and L2/3 regulari-
zations permit an analytically expressive thresholding rep-
resentation [19]. In the literature [19], Xu et al.
investigated that when 0 < q < 1/2, there are not obvious
difference in the variable selection performance of Lq (0 <
q < 1/2) regularization, but solving the L1/2 regularization
is much efficient compared to the L0 regularization. On
the other hand, the L1/2 regularization can yield most
sparse solutions among Lq (1/2 < q < 1) regularizations.
Moreover, they also proved some attractive properties of
the L1/2 regularization, such as unbiasedness, sparsity and
oracle properties. Our previous works have also demon-
strated the efficiencies of L1/2 regularization for Cox and
AFT models respectively [20]. The sparse L1/2 regularization
model has expressed as:






ð4ÞTable 2 The detail information of four real gene expression
datasets used in the experiments
Datasets No. of genes No. of samples No. of censored
DLBCL (2002) 7399 240 102
DLBCL (2003) 8810 92 28
Lung cancer 7129 86 62
AML 6283 116 49where l is loss function and λ is tuning parameter. Since
the penalty function of L1/2 regularization is nonconvex,
which raises numerical challenges in fitting the Cox and
AFT models. Recently, coordinate descent algorithms
[21] for solving nonconvex regularization approach
(such as SCAD, MCP) have been shown significantly ef-
ficiency and convergence [22]. The algorithms optimize
a target function with respect to a single parameter at a
time, iteratively cycling through all parameters until
reached its convergence. Since the computational bur-
den increases only linearly with the number of the co-
variates p, coordinate descent algorithms can be a
powerful tool for solving high-dimensional problems.
Therefore, in this paper, we introduce a novel univari-
ate half thresholding operator of the coordinate descent
algorithm for the L1/2 regularization, which can be
expressed as:





















(j) = ∑k ≠ jxikβk as the partial residual for fitting βj,
ωj = ∑i = 1
n xij(yi − y˜i




Remark: In our previous work [23], we used 34 λð Þ
2
3 for
represent L1/2 regularization thresholding operator. Here,












Fig. 4 The CI obtained by the Cox and AFT models with and without semi-supervised learning approach for the four gene expression datasets





3 . This new value is more precisely and effectively
than the old one. Since it is known that the quantity of the
solutions of a regularization problem depends seriously on
the setting of the regularization parameter λ. Based on this
novel thresholding operator, when λ is chosen by some effi-
cient parameters tuning strategy, such as cross-validation,
the convergence of the algorithm is proved [24].Our proposed semi-supervised learning method
Figure 1 illustrates the overview of our proposed semi-
supervised learning development and evaluation workflow.
Microarray gene expression data on a specific cancer type
are collected, processed, and separated into completed
samples and censored samples. In order to identify tumor
subclasses that were both biologically meaningful and clin-
ically relevant, we applied the L1/2 regularized Cox model
on the completed data to select a group of outcome-


















Fig. 5 The number of genes selected by the Cox and AFT models with an
expression datasetsand censored cases can be subsequently classified into
“low-risk” and “high-risk” classes. Once such classes are
identified, we can evaluate the censored data using the
mean imputation approach based on the completed data
belonged to the same risk classes, because they are corre-
lated to similar disease biologically meaningful at the mo-
lecular level. When the censored data replaced by the
appropriate imputation values, the L1/2 regularized AFT
model can be used to select a list of genes that correlate
with the clinical variable of interest, and reevaluate the
censored data based on these selected genes. A stratified
K-fold cross-validation is used for regularization parameter
tuning. We repeated this semi-supervised learning proced-
ure including Cox and AFT steps multiple time with in-
creasing number of available training data and estimating
the censored data based on the similar genotype disease.
In the semi-supervised learning framework, the pre-
dictive accuracy of the Cox and AFT models would be












d without semi-supervised learning approach for the four gene
(a) Cox (b) Semi-Cox
Fig. 6 The survival curves of the Cox model with and without the semi-supervised learning method for AML dataset
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ably. The L1/2 regularization approach can select the sig-
nificant relevant gene sets based on the Cox and AFT
models respectively.
In our proposed semi-supervised learning method, the
censored data are evaluated from the same risk class to
improve prediction performance. However, there are
some observable errors in the imputations of the cen-
sored data. For example, the estimated survival time by
AFT model was even less than the censored time. We
regarded them as error estimations, and would not use
them for model training.
In this paper, two parameters were used to test the
performances obtained by different methods.
Integrated Brier-Score (IBS)
The Brier Score (BS) [25] is defined as a function of time
t > 0 by:




S^ tjXið Þ21 ti≤t∧δi ¼ 1ð Þ
G^ tið Þ
þ 1−S^ tjXið Þ
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Fig. 7 The percentage of different types of data processed by the semi-supwhere Ĝ(⋅) denotes the Kaplan-Meier estimation of the
censoring distribution and Ŝ(⋅|Xi) stands to estimate sur-
vival for the patient i. Note that the BS(t) is dependent on
the time t, and its values are between 0 and 1. The good
predictions at the time t result in small values of BS. The





BS tð Þdt ð7Þ
The IBS is used to assess the goodness of the predicted
survival functions of all observations at every time
between 0 and max(ti).
Concordance Index (CI)
The Concordance Index (CI) can be interpreted as the
fraction of all pairs of subjects which predicted survival
times are correctly ordered among all subjects that can
actually be ordered. By the CI definition, we can deter-
mine ti > tj when fi > fj and δj = 1 where f(⋅) is survival









































Fig. 8 The percentage of correct and error classification obtained by our proposed semi-supervised learning model in simulated experiment
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1 ti < tj∧δi ¼ 1
  ð8Þ
Note that the values of CI are between 0 and 1, the
perfect predictions of the building model would lead to
1 while have a CI of 0.5 at random.
Results
Simulated experiment
We adopted the simulation scheme in R. Bender’s work
[26]. The generation procedure of the simulated data is
as follows:
Step 1: we generate γi0, γi1,…, γip (i = 1,…,n)
independently from standard normal distribution







(j = 1,…, p) where ρ
is the correlation coefficient.
Step 2: The survival time yi is written as: yi ¼ 1α log
1− α log Uð Þω exp βXð Þ

 
which U is an uniformly distributed
variable, ω is the scale parameter, α is the shape
parameter.
Step 3: Censoring time point yi′(i = 1,…n) is obtained
from an random distribution E (θ), where θ is
determined by specify censoring rate.
Step 4: Here we define yi =min(yi, yi′) and δi = I(yi < yi′),
the observed data represented as (yi, xi, δi) for the
model are generated.
In our simulated experiments, we build high-dimensional
and low sample size datasets. In every dataset, the dimen-
sion of the predictive genes is p = 1000, in which 10 prog-
nostic genes and their corresponding coefficients are
nonzero. The coefficients of the remaining 990 genes arezero. About 40 % of the data in each subgroup are right
censored. We considered the training sample sizes are
n = 100, 200, 300 and the correlation coefficients of
genes areρ = 0 and ρ = 0.3 respectively. The simulated
data were applied to the single Cox, single AFT and
semi-supervised learning approach with Cox and AFT
models. For gene selection, we use L1/2 regularization
approach and the regularization parameters are tuned
by 5-fold cross validation. To assess the variability of
the experiment, each method is evaluated on a test set
including 200 samples, and replicated over 50 random
training and test partitions.
Figure 2 shows the percentage of data distribution
processed by our semi-supervised learning model with
L1/2 regularization in different parameter settings (a: n =
100, ρ = 0.3; b: n = 100, ρ = 0; c: n = 200, ρ = 0.3; d: n =
200, ρ = 0; e: n = 300, ρ = 0.3; f: n = 300, ρ = 0;). The first
cylinder represents the simulated dataset, and the
cylinders a-f present the form of the dataset processed
by our semi-supervised learning model. Compared to
the original dataset, the most censored data can be
reasonable estimated to the available data by semi-
supervised learning model. For example, when the
training sample n = 300 and the correlation coeffi-
cientρ = 0, just 2.41 % censored data cannot conjugate
into the available samples because their imputed sur-
vival time based on the AFT model is smaller than
their observed censored time. Moreover, we can see
that with the sample size increases or the correction
coefficient decreases, more censored data can be correctly
estimated to available training data.
The classification accuracy under the correlation coef-
ficient ρ = 0.3 with different training sample size setting
was demonstrated in Fig. 3, the sum of red and blue part
represent the samples which can be correctly classified
by the Cox model. The first cylinder in each group rep-
resents the result obtained by Cox model, and the sec-
ond one represents the result obtained by our semi-
supervised learning model. No matter in which group,
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improvements of the classification performance. When
the training sample size n = 100, 200, 300, more than
32.23, 20.55 and 15.63 % samples were correctly classi-
fied by semi-Cox model when comparing with the re-
sults of the single Cox model.
The precision of our semi-supervised learning model
with L1/2 regularization was given in Table 1. The preci-
sion is got from the number of correct selected genes
divided the total number of selected genes by the
methods. With the sample size increase or the correc-
tion coefficients of the features decrease, the classifica-
tion performances of each model become better. We
found the single Cox and single AFT model is difficult
to select the whole correct genes in the dataset. This
means these models selected too few corrected genes
and many other irrelevant genes in their results. This
made their prediction precision very low. Nevertheless,
our semi-supervised learning model solves this problem,
the precisions of the semi-Cox or the semi-AFT were
both higher than that obtained by the single Cox or sin-
gle AFT model. After processed by our semi supervised
learning method, the number of selected correct genes
was increased, and the number of total selected genes
were decreased, the semi-Cox achieved about 130 % im-
provements in precision compared to the single Cox
model. Although the precision improvement of semi-
AFT model is smaller than that of the semi-Cox model,
it can select most correct genes under different param-
eter settings. Therefore we think our semi-supervised
learning method can significantly improve the accuracy
of prediction for survival analyses with the high-
dimensional and low sample size gene expression data.Simulation analysis of real microarray datasets
In this section, the proposed semi-supervised learn-
ing approach was applied to the four real gene ex-
pression datasets respectively, such as DLBCL (2002)
[27], DLBCL (2003) [28], Lung cancer [29], AML
[30]. The brief information of these datasets is sum-
marized in Table 2.
In order to accurately assess the performance of the
semi-supervised learning approach, the real datasets
were randomly divided into two pieces: two thirds of the
available patient samples, which include the completed
and correct imputed censored data, were put in the
training set used for estimation and the remaining com-
pleted and censored patients’ data would be used to test
the prediction capability. We used single Cox and single
AFT with L1/2regularization approaches for comparisons
and for each procedure, the regularization parameters
are tuned by 5-fold cross validation. All results in this
article are averaged over 50 repeated times respectively.As show in Fig. 4, our proposed semi-supervised learn-
ing method can significantly increase the available sam-
ple size for classification model training. Especially, in
Lung cancer dataset, the available samples increase from
27.91 to 94.19 %. For other three datasets, the available
sample sizes also augment from 57.50, 69.56, 57.75 to
96.67, 96.73, 94.84 % respectively. Most censored data
were accurately estimated by the AFT model using sam-
ples, which belong to the same genotype disease classes,
and were sequentially classified into high-risk or low-
risk classes by the Cox model respectively. In addition of
that, just small part of the censored data cannot conju-
gate into the available samples because their imputed
survival time based on the AFT model is smaller than
their observed censored time. The reason may be the in-
dividual differences of the patients.
The integrated brier score (IBS) and the concordance
index (CI) measurements were used to evaluate the classi-
fication and prediction performance of Cox and AFT
models in the semi-supervised learning approach. In the
IBS measure, the lower value means the more accurate
prediction result. As shown in Fig. 5, the values of IBS ob-
tained by our semi-supervised learning model with L1/2
penalty were smaller than that obtained by the single Cox
and AFT models. For example, in the Lung cancer dataset,
the IBS values of the Cox and AFT models from 0.2164
and 0.2195 improve to 0.1259 and 0.1341 respectively in
the semi-supervised learning approach. For the other gene
expression datasets DLBCL2002, DLBCL2003 and AML,
the IBS values of the Cox model improve 34, 45 and 26 %,
and the IBS values of the AFT model improve 34, 36 and
28 % respectively. This means that our proposed semi-
supervised learning approach can significantly improve
the classification and prediction accuracy of the Cox and
AFT models. In Fig. 6, the values of CI measure obtained
by Cox and AFT with and without the semi-supervised
learning approaches were given respectively. The CI
values belong to the regain [0.5, 1] and its larger value
means the more accurate prediction results. As shown in
Fig 6, for the Lung cancer dataset, the CI values of the
Cox and AFT models from 0.5738 and 0.6013 improve to
0.6620 and 0.7225 respectively in the semi-supervised
learning approach. The improvement rate is higher than
(0.6620-0.5738)/(0.5738-0.500) = 120 %. For the other
gene expression datasets DLBCL2002, DLBCL2003 and
AML, the CI values of the Cox models improve 39, 45
and 25 %, and the CI values of the AFT models improve
56, 45 and 36 % respectively. These also illustrated the
semi-supervised learning method can significantly im-
prove the accuracy of prediction in survival analysis with
the high-dimensional and low sample size gene expression
data.
Figure 7 gives the number of genes selected by the
L1/2regularized Cox and AFT models with and without
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and semi-AFT selected less genes compared to the single
Cox and the AFT model. For example, in the lung cancer
dataset, the single Cox and single AFT models select 14
and 22 genes respectively. However, the Cox and AFT
models just select 10 and 17 genes in semi-supervised
learning model. Moreover, Combined the found in the
Figs. 5 and 6, the prediction accuracy of Cox and AFT in
the semi-supervised learning model was significantly im-
proved using more relevant genes.
On the other hand, we find that for these all four
gene expression datasets, the selected genes from Cox
and AFT models are quite different and just small
parts are overlapping. We think the reason may be
that the regularized Cox model selects the relevant
genes for low-risk and high-risk classification. Nerve-
less, the genes selected by the AFT model are high
correlation for the survival time of patients. So these
two models may select different genes, which have
different biological function. Through our below ana-
lyses, we know that the genes selected by semi-
supervised learning methods are significant relevant
with the cancer.
Figure 8 shows the survival curves of the Cox model
with and without the semi-supervised learning method
for AML dataset. The x-axis represents the survival days
and the y-axis is the estimated survival probability. The
green and read curves represent the changes of the sur-
vival probability for the “low-risk” and “high-risk” clas-
ses respectively. As show in Fig. 8a, these two curves
intersect at the time point of 564 day, which means
that the single Cox cannot efficiently classify and pre-
dict the survival rate of the patients using the AML
dataset. On the contrary, in Fig. 8b, the survival prob-
abilities of the “low-risk” and “high-risk” patients can
be efficiently estimated by the semi-Cox model. For
other three gene expression datasets, we also got the
similar results, which are the classification perform-
ance of semi-Cox model significantly outperforms the
single Cox model.
Discussion
In this section, we introduce a brief biological discussion
of the selected genes for the Lung cancer dataset to
demonstrate the superiority of our proposed semi-
supervised learning method. The number of selected
genes by semi-supervised learning method is less than
the single Cox and AFT model, but includes some genes
which are significantly associated with cancer and can-
not be selected by the two single Cox and AFT models,
such as GDF15, ARHGDIB and PDGFRL. GDF15 be-
longs to the transforming growth factor-beta superfam-
ily, and is one kind of bone morphogenetic proteins. It
was showed that GDF15 can be seen as prognosticationof cancer morbidity and mortality in men [31]. ARHG-
DIB is the member of the Rho (or ARH) protein family;
it is involved in many different cell events such as cell
secretion, proliferation. It is likely to impact on the can-
cer [32]. The role of PDGFRL is to encode a protein
contains an important sequence which is similar to the
ligand binding domain of platelet-derived growth factor
receptor beta. Biological research has confirmed that this
gene can affect the sporadic hepatocellular carcinomas.
This suggests that this gene product may get the func-
tion of the tumour inhibition.
At the same time, the Cox and AFT models with
and without semi-supervised learning method also
selected some common genes. For example,the
PTP4A2, TFAP2C, GSTT2. PTP4A2 is the member of
the protein tyrosine phosphatase family, overexpres-
sion of PTP4A2 will confer a transformed phenotype
in mammalian cells, which suggested its role in
tumorigenic is [33]. TFAP2C can encode a protein
contains a sequence-specific DNA-binding transcrip-
tion factor which can activate some developmental
genes [34]. GSTT2 is one kind of a member of a
superfamily of proteins. It has been proved to play an
important role in human carcinogenesis and shows
that these genes are linked to cancer with a certain
relationship [35].
Through the comparison of the biological analyses of
the selected genes, we found the semi-supervised
method based on Cox and AFT models with L1/2
regularization is a competitive method compared to sin-
gle regularized Cox and AFT models.
Conclusion
To overcome the limitations of fully unsupervised and
fully supervised approaches for survival analysis in
cancer research, we have developed a discriminative
semi-supervised method based on Cox and AFT models
with L1/2 regularization. This method combines the ad-
vantages of both Cox and AFT models, and overcome
the dilemma in their applications. By comparison the
results of Cox and AFT modes with and without the
semi-supervised method in simulation experiment and
real microarray datasets experiment with different regu-
larizing method, we demonstrated that 1) the censored
data could be employed after appropriate processing; 2)
the semi-supervised classification improved prediction
accuracy as compared to the state of the art single Cox
model; 3) the gene selection performance gain improved
with the increase number of available samples. There-
fore, for clinical applications, where the goal is often to
develop an accurate predicting test using fewer genes in
order to control cost, the semi-supervised method based
on Cox and AFT models with L1/2 regularization can be
chosen to applied, it will be an efficient and accuracy
Liang et al. BMC Medical Genomics  (2016) 9:11 Page 11 of 11method based on the high-dimensional and low-sample
size data in cancer survival analysis.
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